



Impact of CYP2D6 Polymorphisms on Propranolol Response in Children with Portal Hypertension

Thesis

*Submitted for Partial Fulfillment of the Requirements of
Medical Doctorate of Medical and Clinical Genetics*

By

Radwa Gamal Mahmoud Taha

*(M.B.B.CH., Ain Shams University, 2009)
(Master Degree of Medical and Clinical Genetics 2014)*

Supervised by

**Prof. Rabah Mohamed
Shawky**

*Prof. of Pediatrics and Genetics
Faculty of Medicine,
Ain Shams University*

**Prof. Tawhida Yassin
Abdel Ghaffar**

*Professor of Pediatrics
Faculty of Medicine,
Ain Shams University*

Prof. Dr. Solaf Mohamed Elsayed

*Professor of Medical Genetics
Faculty of Medicine, Ain Shams University*

Prof. Dr. Omneya Ibrahim Youssef

*Professor of Pediatrics
Faculty of Medicine, Ain Shams University*

Dr. Tarek Mostafa Kamal

*Consultant for Human Genetics
Faculty of Medicine, Ain Shams University*

Faculty of Medicine, Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I would like to express my respectful thanks and profound gratitude to **Prof. Rabah Mohamed Shawky**, Professor of Pediatrics & Genetics- Faculty of Medicine- Ain Shams University, **Prof. Tawhida Yassin Abdel Ghaffar**, Professor of Pediatrics - Faculty of Medicine- Ain Shams University, **Prof. Solaf Mohamed Elsayed**, Professor of Genetics- Faculty of Medicine- Ain Shams University, **Prof. Omneya Ibrahim Yousef**, Professor of Pediatrics - Faculty of Medicine- Ain Shams University, **Dr. Tarek Mostafa Kamal**, Consultant of Medical Genetics, Faculty of Medicine, Ain Shams University, for their keen guidance, kind supervision, valuable advice and continuous encouragement and generous cooperation.*

*Thanks to my **family** and colleagues for supporting me through this work.*

*Thanks and appreciation to all **patients** participated in this study.*

Radwa Gamal

List of Contents

Title	Page No.
List of Tables.....	5
List of Figures	8
List of Abbreviations.....	9
Introduction	- 1 -
Aim of the Study	12
Review of Literature	
▪ Portal Hypertension	13
▪ Polymorphism of Human Cytochrome P450 2D6.....	33
▪ Propranolol	42
▪ Heart Rate Variability	46
Subjects and Methods.....	58
Results.....	68
Discussion	106
Summary and Conclusion	133
Recommendations.....	137
References	138
Appendix	182
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table 1:	Different genotypes with drug metabolizing phenotypes	66
Table 2:	Demographic data of the studied patients.....	68
Table 3:	Distribution of the presenting symptoms and signs of studied patients.....	69
Table 4:	Laboratory data of studied patients	71
Table 5:	Abdominal ultrasound findings of studied patients	72
Table 6:	Basal abdominal Doppler ultrasound findings of studied patients (excluding the 5 patients who were already responders at the beginning)	73
Table 7:	Stage of fibrosis as measured by Fibroscan in studied patients	74
Table 8:	Basal measurements of pulse, blood pressure and Propranolol dose of studied patients	75
Table 9:	HRV time domain measures data in studied patients as regards etiology of portal hypertension	76
Table 10:	Genotypes of the study population.....	77
Table 11:	Alleles segregation among population groups of the study	78
Table 12:	Characteristics of studied patients in each genotype	79
Table 13:	Characteristics of patients who had their pulse already 20-25% decreased at beginning of the study	80
Table 14:	Comparison of patients who had their pulse decreased to 25% as regards etiology of portal hypertension.....	82

List of Tables (cont...)

Table No.	Title	Page No.
Table 15:	Comparison of the basal and end study vital data and dose of Propranolol of the 16 patients who had their pulse decreased to 25%	82
Table 16:	Comparison between patients with positive and negative decrease pulse 25% as regards history and clinical data	83
Table 17:	Comparison between patients with positive and negative decrease pulse 25% as regards vital data and Propranolol dose	84
Table 18:	Comparison between patients with positive and negative decrease pulse 25% as regards laboratory data of studied patients.	85
Table 19a:	Comparison between patients with positive and negative decrease pulse 25% as regards basal Doppler findings.....	86
Table 19b:	Comparison between patients with positive and negative decrease pulse 25% as regards end study Doppler	78
Table 20:	Comparison between patients with positive and negative decrease pulse 25% as regards endoscope findings.....	88
Table 21:	Comparison between patients with positive and negative decrease pulse 25% as regards Fibroscan results	89
Table 22a:	Comparison between patients with positive and negative decrease pulse 25% as regards basal HRV data.....	90
Table 22b:	Comparison between patients with positive and negative decrease pulse 25% as regards end study HRV data	82

List of Tables (cont...)

Table No.	Title	Page No.
Table 23:	Comparison between patients with positive and negative decrease pulse 25% as regards CYP2D6 metabolizer phenotypes and genotypes.....	92
Table 24:	Side effects of Propranolol in the studied group	93
Table 25:	Dose of Propranolol in 9 patients who developed side effects and metabolizer phenotype	95
Table 26:	Comparison between patients with positive and negative decrease pulse 25% as regards side effects which hindered the increase of Propranolol to reach effective dose.....	96
Table 27:	Comparison between PMs and EMs as regards history of clinical data.....	97
Table 28:	Comparison between PMs and EMs as regards Propranolol dose at end study	98
Table 29:	Comparison between PMs & EMs as regards laboratory data	99
Table 30a:	Comparison between PMs and EMs as regards basal Doppler ultrasound findings.....	100
Table 30b:	Comparison between PMs and EMs as regards end study Doppler ultrasound findings.....	92
Table 31:	Comparison between PMs and EMs as regards endoscope findings	102
Table 32:	Comparison between PMs and EMs as regards Fibroscan stage and side effects	103
Table 33a:	Comparison between PMs & EMs as regards basal HRV time domain data	104
Table 33b:	Comparison between PMs & EMs as regards end study HRV data.....	96

List of Figures

Fig. No.	Title	Page No.
Figure 1:	Correlation between liver stiffness(kPa) and fibrosis stage.....	60
Figure 2:	CYP2D6 wild Heterozygous/ 1934G>A (*1/*4)EM.....	66
Figure 3:	CYP2D6 wild/CYP2D6 wild homozygous (*1/*1)or CYP2D6 wild/ CYP2D6 gene deletion wild compound heterozygous (*1/*5) EM.....	67
Figure 4:	Distribution of the presenting symptoms and signs of studied patients.	70
Figure 5:	Percentage of patients with a decrease pulse 20-25% at the end of study.....	81
Figure 6:	Percentage of studied patients who developed side effects which hindered the increase of propranolol to reach effective dose.	94
Figure 7:	Distribution of side effects which hindered the increase of propranolol to reach effective dose.	94

List of Abbreviations

Abb.	Full term
<i>ALT</i>	<i>Alanine transaminase,</i>
<i>AST</i>	<i>Aspartate aminotransferase,</i>
<i>CBC</i>	<i>Complete blood picture</i>
<i>CHF</i>	<i>Congenital hepatic fibrosis</i>
<i>EM</i>	<i>Extensive metabolizerCYP2D6: cytochrome P450 2D6</i>
<i>fl</i>	<i>Femtoliters</i>
<i>GGT</i>	<i>Gamma glutamyl transferase.</i>
<i>HR</i>	<i>Heart rate</i>
<i>HRV</i>	<i>Heart rate variability</i>
<i>HVPG</i>	<i>Hepatic Venous Pressure Gradient</i>
<i>INR</i>	<i>International Normalized Ratio</i>
<i>LSM</i>	<i>Liver-stiffness measurement</i>
<i>MCH</i>	<i>Mean corpuscular hemoglobin,</i>
<i>MCV</i>	<i>Mean corpuscular volume,</i>
<i>PHG</i>	<i>Portal hypertensive gastropathy</i>
<i>PM</i>	<i>Poor metabolizer</i>
<i>PV</i>	<i>Portal vein</i>
<i>PVT</i>	<i>Portal vein thrombosis</i>
<i>TLC</i>	<i>Total leukocyte count,</i>
<i>US</i>	<i>Ultrasound</i>

INTRODUCTION

Portal hypertension is defined by elevation of hepatic venous pressure gradient (HVPG) greater than 5 mm Hg and it is considered to be clinically significant when HVPG exceeds 10 to 12 mm Hg (*Fernandez, 2019*).

It is classified based on anatomical location as prehepatic, intrahepatic, or post hepatic portal hypertension. Patients usually present with splenomegaly, life threatening gastrointestinal bleeding and ascites (*Simonetto et al., 2019*).

The goals of pharmacotherapy treatment of portal hypertension are to reduce mortality and morbidity and prevent complications associated with acute bleeding related to portal hypertension. Two main categories of drugs, vasoconstrictors and vasodilators, are used. The vasoconstrictors are used to treat acute bleeding in patients with portal hypertension before performing endoscopy (*Garcia-Tsao et al., 2003*). Vasodilators such as isosorbide mononitrate (ISMN) reduce intrahepatic vascular resistance without decreasing peripheral or portal-collateral resistance. Beta-blockers are used to provide primary and secondary prophylaxis (*Steenen et al., 2016*).

Propranolol is a synthetic non-selective beta-adrenergic receptor blocking agent used in primary and secondary prevention of variceal bleeding in both patients with cirrhosis and non cirrhotic portal hypertension (*Suk et al., 2007*).

The reduction of heart rate (HR) is still most widely used to direct the administration of propranolol and predict the hemodynamic response (**Zhang et al., 2016**).

Propranolol acts on the autonomic nervous system and HRV can be used to explore its influence on sympathetic and parasympathetic activity (**Ernst, 2017**).

CYP2D6 is the rate-limiting enzyme for the metabolism of propranolol and it is involved in its phase I metabolism. CYP2D6 is highly polymorphic and its polymorphisms are based on extent of drug metabolism which includes 4 classes of phenotype (**Ingelman-Sundberg et al., 1999**).

Factors that influence cytochromes P450 expression and function include genetic polymorphism, epigenetic influences on drug metabolism and non-genetic host factors (**Zanger and Schwab, 2013**).

AIM OF THE STUDY

PPrimary goal: To study CYP2D6 polymorphism in Egyptian children with presinusoidal portal hypertension and the correlation of this polymorphism with the effects of propranolol.

Secondary goal: To study the correlation between effective propranolol dose and etiology of portal hypertension.

Chapter 1

PORTAL HYPERTENSION

Definition

Portal hypertension (PHT) indicates increased pressure in portal venous system. Hepatic Venous Pressure Gradient (HVPG) is the difference between the wedged hepatic venous pressure and free hepatic venous pressure. A normal HVPG is 3-5 mmHg. An HVPG above 5 mmHg defines portal hypertension, however an HVPG of 10 mmHg or greater defines clinically significant portal hypertension (*Fernandez, 2019; Ripoll et al., 2009*).

Etiology of PHT

The causes for portal hypertension are classified as (*Simonetto et al., 2019*).

I- Prehepatic portal hypertension

- 1- Portal Vein Thrombosis
- 2- Splenic Vein Thrombosis

II- Intrahepatic portal hypertension

III- Post-hepatic portal hypertension

I- Prehepatic portal hypertension

Prehepatic portal hypertension is an infrequent condition in which increased portal pressure is caused by obstruction of the portal venous tree before it enters the liver. The site of obstruction may be limited to the splenic or mesenteric veins, but most commonly the portal vein is involved (*Fernandez, 2019*).

1-Portal Vein Thrombosis

Definition of portal vein thrombosis (PVT): Total or near-total obstruction of blood flow (*Harmanci and Bayraktar, 2007*).

Etiology of PVT

PVT is the most frequent cause of prehepatic portal hypertension. PVT has various causes. In previous studies, PVT were attributed mostly to trauma (5%-17%), intraabdominal sepsis (5%-36%), umbilical sepsis (5%-12%), pancreatitis (4%-5%) and prothrombotic disorders (2%-28%), but in nearly 50% of the patients etiology remained unidentified (*Intagliata et al., 2019; Cardin et al., 1992*).

In children, a history consistent with omphalitis or umbilical catheterization can be often obtained. In adults, the cause of portal thrombosis is less frequently identified.

Other risk factors for PVT include factor II mutation, protein C, protein S deficiency and antithrombin deficiency (*Trebicka and Strassburg, 2014*).

Complications of PVT

The majority of complications of long-standing PVT are due to portal hypertension (*Intagliata et al., 2019*). Collateralization of the portal vein might lead to the development of the so-called portal cavernoma (*Ogren et al., 2006*). However, portosystemic shunting can also develop, since these cavernous collaterals may not sufficiently drain the portal blood flow, and portal pressure is not sufficiently decreased. This usually presents as de novo appearance and/or progression of gastric or esophageal varices and may be complicated by bleeding (*Yerdel et al., 2000*). Bleeding due to PVT occurs about 100 times more often in patients with cirrhosis (*Intagliata et al., 2019*).

Another but less frequent complication of collateral vessel formation is the portosystemic shunting in some patients, which leads to subclinical hepatic encephalopathy (*Ogren et al., 2006*).

2- Splenic Vein Thrombosis

Splenic vein thrombosis may be either symptomatic or asymptomatic. Gastrointestinal bleeding at varying severity is the most common manifestation of this syndrome. The main